JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD B. Pharmacy IV PHARMACOVIGILANCE Previous Question Paper (July/August-2022 - R17)

Safety monitoring of drugs, known as pharmacovigilance, is essential because clinical trials are conducted under controlled conditions with limited sample sizes, durations, and patient populations. It is significant for the following reasons:

• Detection of rare adverse drug reactions (ADRs): Many serious side effects occur only in a small percentage of the population and may not appear until a drug is used by millions of people in real-world settings.
• Identification of long-term effects: Chronic toxicity, carcinogenicity, or reproductive effects may only manifest after prolonged exposure, which is often beyond the scope of pre-marketing trials.
• Assessment of drug-drug and drug-food interactions: Real-world usage involves polypharmacy and diverse dietary habits that are rarely fully captured during clinical development.
• Risk-benefit profile maintenance: It allows for the continuous evaluation of a drug's safety profile, ensuring that the therapeutic benefits continue to outweigh the potential risks throughout its life cycle.
• Public health protection: It provides the data necessary for regulatory bodies to issue safety alerts, update package inserts, restrict usage, or withdraw unsafe medications from the market to prevent harm.

The Pharmacovigilance Program of India (PvPI), coordinated by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare, plays a pivotal role in ensuring drug safety in India. Its core responsibilities include:

• ADR Monitoring and Reporting: PvPI establishes a nationwide network of Adverse Drug Reaction Monitoring Centres (AMCs) to collect, collate, and analyze safety data from healthcare professionals and patients.
• Data Analysis and Signal Detection: It utilizes the VigiFlow software to manage and analyze ADR reports to identify potential safety signals or previously unknown associations between drugs and adverse events.
• Regulatory Recommendations: Based on its findings, PvPI provides evidence-based recommendations to the Central Drugs Standard Control Organization (CDSCO) regarding regulatory actions, such as label changes, black-box warnings, or product recalls.
• Capacity Building and Training: It conducts training programs for healthcare professionals to improve the culture of spontaneous reporting and ensure high-quality data collection.
• Public Awareness: PvPI promotes patient safety by educating the public on the importance of reporting side effects and the safe use of medicines.
• International Collaboration: It acts as a national center for the WHO Programme for International Drug Monitoring, contributing Indian safety data to the global VigiBase database to support international pharmacovigilance efforts.